The approval document of clinical trial for the new drug of type 1.1 of Sihuan Medicine Diabetes

Recently, Sihuan pharmaceutical announced that its main R & D innovative drug for diabetes treatment "jiaglijing" has successfully obtained the clinical approval document from the State Food and drug administration, which is the second type 1.1 patent innovative drug for diabetes treatment after eglitaine hydrochloride It is reported that gaggliptin is a new type of SGLT2 inhibitor and is intended to be used for the treatment of type II diabetes Patent applications have been filed in China, the United States, Europe, Japan and South Korea SGLT2 is a new target for the treatment of type II diabetes in the world SGLT2 inhibitors can inhibit the reabsorption of glucose by the kidney, increase the excretion of urine glucose, and effectively reduce the blood glucose level It is worth noting that SGLT2 inhibitor is the only kind of antidiabetic drug that has been confirmed by clinical research and has heart protective effect on diabetic Its mechanism of action avoids the serious adverse reactions such as weight gain and hypoglycemia caused by traditional oral antidiabetic drugs, and can be used in combination with other antidiabetic drugs The incidence rate of diabetes is increasing The number of people worldwide is nearly 400 million The prevalence of diabetes in China is increasing rapidly Currently, there are 92 million diabetics in China, and the potential patients are estimated to be close to 150 million China has become the country with the largest number of diabetics in the world According to the data of Ames market research company, China's diabetes market reached 15.6 billion yuan (excluding devices) in 2013 With the aging of China's population and the aggravation of urbanization, the incidence rate of diabetes is believed to be further improved The size of Chinese diabetes market is expected to reach 40 billion yuan, and the market potential is huge.